Related Experiment Video
Updated: Jan 15, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
AI-powered programmable virtual humans toward human physiologically-based drug discovery
You Wu1, Philip E Bourne2, Lei Xie3
1School of Pharmacy and Pharmaceutical Sciences & Center for Drug Discovery, Northeastern University, Boston, MA, USA; Ph.D. Program in Computer Science, The Graduate Center, The City University of New York, New York, NY, USA.
None:
Artificial intelligence (AI) has generated great interest in drug discovery, but current approaches merely digitize existing experiments, failing to predict clinical outcomes of new compounds. Likewise, pharmacology digital twins, designed for late-phase drug development, lack the ability to bridge translational gaps, limiting their value in early-stage drug discovery. The true potential of AI lies in enabling virtual experiments impossible in the real world, 'testing' novel compounds directly within the human body. Advances in AI, high-throughput assays, and single-cell and spatial omics now enable programmable virtual humans: dynamic, multiscale models that establish a new paradigm of physiologically-based drug discovery. This approach offers a transformative path to evaluate and optimize compound efficacy and safety earlier than ever in the drug discovery process.
More Related Videos
Related Concept Videos
Model Approaches for Pharmacokinetic Data: Physiological Models
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

